Issue link: http://uwashington.uberflip.com/i/102670
Hansten P, Horn JR, The Top 100 Drug Interactions: A Guide to Patient Management. Freeland, WA: H&H Publications; 2012. Kelly EJ, Yarov-Yarovoy V, Rettie AE. CYP4B1 (cytochrome P450, family 4, subfamily B, polypeptide 1). Atlas Genet Cytogenet Oncol Haematol 2012. Harrelson JP, Stamper BD, Chapman JD, Goodlett DR, Nelson SD. Covalent Modification and Time-Dependent Inhibition of Human CYP2E1 by the Meta Isomer of Acetaminophen. Drug Metab Dispos 2012. Kelly EJ, Nakano M, Rohatgi P, Yarov-Yarovoy V, Rettie AE. CYP4V2 and CYP4F22: Orphan P450s for orphan ocular and skin diseases. Mol Interventions 2011. Hebert MF. Impact of Pregnancy on Maternal Pharmacokinetics of Medications (chapter). Clinical Pharmacology During Pregnancy. New York, NY: Academic Press; In Press. (Ed. Mattison D). Ho HT, A Dahlin, Wang J. Expression profiling of solute carrier gene families at the bloodCSF barrier. Frontiers in Neuropharm. E-pub 2012. Ho HT, Xia L, Wang J. Residue Ile89 in human plasma membrane monoamine transporter influences its organic cation transport activity and sensitivity to inhibition by dilazep. Biochem Pharmacol 2012. Ho RJ. A New Collaboration Platform for Improving Clinical Drug Development (Editorial). J Pharm Sci 2011. Horn JR. Important Drug Interactions and Their Mechanisms (Chapter 66). Basic and Clinical Pharmacology, 12th ed. New York, NY: McGraw-Hill; 2012. (Ed. Katzung B). Kirby BJ, Collier AC, Kharasch ED, Dixit V, Desai P, Whittington D, Thummel KE, Unadkat JD. Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6 and 2C9 by Ritonavir or Nelfinavir. Drug Metab Dispos 2011. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD. Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir. Drug Metab Dispos 2011. Lam AL, Odegard PS, Gardner JS. School of Pharmacy–based medication therapy management program: Development and initial experience. J APhA 2012. Horn JR, Hansten PD. Metoclopramide and Dyskinesia. Pharm Times 2012. Lee KK, Pessi A, Gui L, Santoprete A, Talekar A, Moscona A, Porotto M. Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. J Biol Chem 2011. Ishibe N, Carlson JJ, Ramsey SD, et al. Use of epidermal growth factor receptor mutation analysis in patients with advanced non-smallcell lung cancer to determine erlotinib use as first-line therapy. PLoS Curr 2011. Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biologic agents for treatment of moderate-to-severe psoriasis: A Bayesian network meta-analysis. Arch Dermatol 2012. Isoherranen N, Lutz JD, Chung S, Hachad H, Levy RH, Ragueneau-Majlessi I. Importance of multi-P450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude and prediction from in vitro data. Chem Res Toxicol. E-pub 2012. Liu X, Sirotkin Y, Shen Y, Anderson G, Tsai YS, Ting YS, Goodlett DR, et al. Protein identification using top-down spectra. Mol Cell Proteomics 2011. Jimenez N, Anderson GD, Shen DD, et al. Is ethnicity associated with morphine's side effects in children? Morphine pharmacokinetics, analgesic response and side effects in children having tonsillectomy. Pediatric Anesthesia 2012. Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol 2011. McCune J, Sullivan SD, Clarke L, Blough DK, McDermott C, Malin J, Ramsey SD. Colony stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer receiving chemotherapy. Pharmacother 2012. McCune JS, Woodahl EL, Furlong T, Storer B, Wang J, Heimfeld S, Deeg HJ, O'Donnell PV. A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. Cancer Chemo Pharmacol 2012. McDermott C, Gray SL. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. Ann Pharmacother 2012. McDonald MG, Au NT, Wittkowsky AK, Rettie AE. Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites. Clin Pharmacol Ther 2012. Medina EM, Andrews BT, Nakatani E, Catalano CE. The Bacteriophage Lambda gpNu3 Scaffolding Protein is an Intrinsically Disordered and Biologically Functional Procapsid Assembly Catalyst. J Mol Biol 2011. Medina EM, Nakatani E, Kruse S, Catalano CE. Thermodynamic Characterization of Viral Procapsid Expansion into a Functional Capsid Shell. J Mol Biol 2012. Mornar S, Chan LN, Mistretta S, Neustadt A, Martins S, Gilliam M. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol 2012. Nelson WL. Antihistamines and Related Antiallergic and Antiulcer Agents (Chapter 32). Foye's Principles of Medicinal Chemistry, 7th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2013. (Eds. Lemke TL, Williams DA, et al). Ni ZL, Bikadi Z, Shuster DL, Zhao CS, Rosenberg MF, Mao Q. Identification of proline residues in or near transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. Biochem 2011. Ni ZL, Mao Q. ATP-Binding Cassette Efflux Transporters in Human Placenta. Curr Pharm Biotech 2011. Nurmemmedov EM, Castelnovo M, Medina E, Catalano CE, Evilevitch A. Challenging Packaging Limits and Infectivity of Phage Lambda. J Mol Biol 2012. Odegard PS, Tadeg H, Downing D, et al. Strengthening Pharmaceutical Care in Ethiopia Through Instructional Collaboration. Am J Pharm Ed 2011. Park BK, Boobis A, Clarke S, Goldring CEP, Jones D, Kenna JG, Lambert C. Laverty HG, Naisbitt DJ, Nelson SD, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA. Managing the Challenge of Chemically Reactive Metabolites in Drug Development. Nature Rev Drug Discov 2011. [ 2013 Excellence Report 15 ]